绿康生化(002868) - 2024 Q4 - 年度业绩预告

Financial Performance - The estimated net profit for 2024 is projected to be a loss between 39,000 million and 34,000 million CNY, compared to a loss of 22,182 million CNY in the same period last year, indicating a decline of 75.82% to 53.28%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be a loss between 39,500 million and 34,500 million CNY, down from a loss of 23,078 million CNY last year, reflecting a decline of 71.16% to 49.49%[2] - The basic earnings per share are expected to be a loss between 2.51 CNY and 2.19 CNY, compared to a loss of 1.44 CNY per share in the previous year[2] Revenue Expectations - Revenue is expected to be between 64,000 million and 65,000 million CNY, representing a growth of 26% to 28% compared to 50,700 million CNY in the previous year[4] - The increase in revenue is attributed to the recovery of the breeding industry and rising demand for veterinary raw materials, with the market share of the main product, sulfamethoxazole, increasing year by year[4] Operational Challenges - The company faces impairment of inventory for photovoltaic film raw materials due to price declines[5] - The photovoltaic film business is experiencing underutilization of capacity and rising amortization costs due to intensified competition and supply-demand imbalance in the photovoltaic industry[5] - The goodwill from the acquisition of subsidiary Green Kang Yushan (film materials) will be fully impaired based on prudence due to the aforementioned reasons[5] Financial Reporting and Investor Guidance - The financial data in this earnings forecast has not been audited by an accounting firm, and the final financial results will be disclosed in the 2024 annual report[3][6] - Investors are advised to be cautious and consider investment risks based on the preliminary nature of the financial data presented[6]